Jun. 16 at 6:28 PM
Attached are all comm'l-stage oncology focused bios down 7%+ from closing highs over the last 5 days.
$SNDX has 2 FDA approved drugs. One is 50/50 partner with INCY on Niktimvo. Kadmon Holdings may be a good peer for Niktimvo acquired for
$1.9B. A financier paid
$350MM for a 14% share suggesting a
$2.5B valuation (again SDNX is 50/50). Ziftomenib from
$KURA is a good peer for Revumenib (but has better SE profile). KURA trades for less than cash in the bank.
$AUTL is again trading for cash.
Look at
$IMCR over 12 months & you'll understand their drop. With multiple late data reads in the next 18 months, it would appear M&A is unlikely but of course we could be wrong.
$DAWN announced last week they hired a VP of R&D so it would also appear M&A is out to save shareholders. Ojemda's patent expires in 6/2035. Will Ojemda be more valuable in 2 years (there's enough patient data to know if Firefly will succeed).
This is for entertainment only. This is not investment advice.
